Quarterly faricimab maintenance for neovascular age-related macular degeneration
Faricimab Fixed Quarterly Maintenance for Neovascular Age Related Macular Degeneration: A Prospective Case Series
PHASE4 · Hospital Authority, Hong Kong · NCT06742307
This test will see if faricimab injections every 12–16 weeks can keep neovascular age-related macular degeneration stable after 2–4 initial loading doses.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Hospital Authority, Hong Kong (other gov) |
| Drugs / interventions | faricimab |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06742307 on ClinicalTrials.gov |
What this trial studies
This phase 4, single-centre program gives patients 2–4 initial faricimab loading injections and then attempts a planned quarterly maintenance schedule (every 12–16 weeks) for those who achieve disease inactivity. It enrolls patients over 50 with active subfoveal macular neovascularisation, including both treatment-naïve and recurrent cases, while excluding eyes with recent anti-VEGF, other macular diseases, or recent ocular surgery. The main outcome is stability without recurrence of neovascular activity on the quarterly regimen at a tertiary eye centre in Hong Kong. The work is positioned as a real-world evaluation of a lower-frequency dosing option to reduce treatment burden compared with PRN or treat-and-extend approaches.
Who should consider this trial
Good fit: Ideal candidates are people over 50 with active subfoveal neovascular AMD (types 1–3) who achieve inactivity after 2–4 loading faricimab doses.
Not a fit: Patients who had anti-VEGF treatment in the prior six months, have other macular diseases, or recent ocular surgery are unlikely to qualify and may not benefit from this planned quarterly regimen.
Why it matters
Potential benefit: If successful, this approach could reduce injection frequency and clinic visits while maintaining retinal stability and vision.
How similar studies have performed: Phase 3 trials (TENAYA and LUCERNE) showed faricimab can be effective with individualized intervals up to 16 weeks compared with aflibercept, supporting this dosing concept.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Subjects aged over 50 years, neovascular AMD with foveal involvement, both treatment-naïve and recurrent cases. There were no specific criteria for initial best-corrected visual acuity (BCVA). Only active subfoveal MNV are included, including types 1, 2, and 3. Exclusion Criteria: * eyes that received any anti-VEGF therapy in the prior six months, * eyes with other disease entities (e.g., diabetic macula oedema, retinal vein occlusions, central serous chorioretinopathy, myopicmacular neovascularisation), * concurrent macula laser (except photodynamic therapy) and ocular surgery (e.g., cataract surgery or vitrectomy) in the prior six months and the study period.
Where this trial is running
Hong Kong
- Department of Ophthalmology, United Chrisitian Hospital — Hong Kong, Hong Kong (RECRUITING)
Study contacts
- Study coordinator: Daniel Ho Tak Wong, FRCOphth (UK)
- Email: WHT454@ha.org.hk
- Phone: +852 3949 3411
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Macular Degeneration Choroidal Neovascularization, neovascular age related macular degeneration, faricimab